Genetics: Chromosome 6 BTN2A2 and BTN3A3 (BTN2A1)

Liver (including sinusoids) would be a possibility.

Liver natural killer cells: subsets and roles in liver immunity (2015)

The liver represents a frontline immune organ that is constantly exposed to a variety of gut-derived antigens as a result of its unique location and blood supply. With a predominant role in innate immunity, the liver is enriched with various innate immune cells, among which natural killer (NK) cells play important roles in host defense and in maintaining immune balance. Hepatic NK cells were first described as ‘pit cells’ in the rat liver in the 1970s. Recent studies of NK cells in mouse and human livers have shown that two distinct NK cell subsets, liver-resident NK cells and conventional NK (cNK) cells, are present in this organ.

Here, we review liver NK cell subsets in different species, revisiting rat hepatic pit cells and highlighting recent progress related to resident NK cells in mouse and human livers, and also discuss the dual roles of NK cells in liver immunity.

Web | PDF | Nature Cellular & Molecular Immunology | Open Access
 
That's really interesting! Do you have any ideas about where these primed cells might be hiding?
No clue, just a point against less NK action in circulation (amongst other things). Anyway I don’t want to get anyone carried away with my thoughts before the data is published and able to be weighed and scrutinised by the community, just thought it was relevant
 
Liver (including sinusoids) would be a possibility.

Liver natural killer cells: subsets and roles in liver immunity (2015)

The liver represents a frontline immune organ that is constantly exposed to a variety of gut-derived antigens as a result of its unique location and blood supply. With a predominant role in innate immunity, the liver is enriched with various innate immune cells, among which natural killer (NK) cells play important roles in host defense and in maintaining immune balance. Hepatic NK cells were first described as ‘pit cells’ in the rat liver in the 1970s. Recent studies of NK cells in mouse and human livers have shown that two distinct NK cell subsets, liver-resident NK cells and conventional NK (cNK) cells, are present in this organ.

Here, we review liver NK cell subsets in different species, revisiting rat hepatic pit cells and highlighting recent progress related to resident NK cells in mouse and human livers, and also discuss the dual roles of NK cells in liver immunity.

Web | PDF | Nature Cellular & Molecular Immunology | Open Access
@mariovitali
 
Maybe a bit far fatched, but Dopamin D2 agonists (Cabergolin, but technically also Abilify) are used to inhibit prolaktin production.
Makes sense.


And then there's this:

 
Does anyone with robust scientific knowledge have the capacity to email the Cambridge uni BTN reseachers? I think its really important we try to get them involved, but I am concerned I might not have the nous to construct a compelling explanation of what was found and the significance of it/what it might suggest. And obviously I have low capacity for this kind of task so it might take me a while.

I am happy to do it if nobody else can but perhaps there is someone else better placed?
 
Also, just thank you for all of your networking. You do a lot of it, and I don’t know if I could express just how much it means to me. It gives me hope.
There is a lot of this that we are all doing behind the scenes that you will not be privy to which i hope is also a source of comfort. this is not to diminish J's efforts but to reassure you that there is a lot of effort being put into trying to help you ASAP that people don't see. i hope that people like myself and J being very forthright on the forum about our activities does not make patients think that others are not doing as much of this stuff

("we" being those who care deeply about the problem - there are many of us)
 
There is a lot of this that we are all doing behind the scenes that you will not be privy to which i hope is also a source of comfort. this is not to diminish J's efforts but to reassure you that there is a lot of effort being put into trying to help you ASAP that people don't see. i hope that people like myself and J being very forthright on the forum about our activities does not make patients think that others are not doing as much of this stuff

("we" being those who care deeply about the problem - there are many of us)
I appreciate your reply! Sometimes it's easy to get loss in hopelessness, and this is a good reminder that there are many people helping in ways that I don't know about.

For example, I didn't know for a bit that you were a researcher, or that many others on here were! It's very cool to see how many researchers there are learning from us here, but also incredibly cool how many researchers are patients themselves.

Thank you @DMissa and thank you all.
 
New Hanson/Grimson team abstract claims to have found GDT cells which produce IFNy are elevated in males only...

Results
Only in ME males is there an increase in the percent of CD27+ γδ T cells, which produce IFNγ. IFNγ targets intracellular pathogens and the increase could implicate an increased response to viral pathogens in ME.

Female ME CD8+ T cells show a chronically stimulated phenotype across T memory subsets, while male ME memory cells show a subset specific activation phenotype.
 
No reply from Birmingham.

We really need some BTN people in here.

The more I think about it the more I thin this is the one lead we are not tracking. James and Alex are running with CA10. OLFM4 could be a good one but it has a neuron role and we are on to neurons. Buspirone we need a clinician for but forestglip has done sterling work on the background (worth a PhD any day). BTNs we have not gnawed the bone yet?

(This is a reference to a favourite phrase of Michael Neuberger, who discovered how B cell antibody diversity is achieved. Sadly, he died of a B cell malignancy.)

The absence of any link to classical MHC (HLA - A-D) and BTNs coming up with a very clear signal as one of the top 8 markers is not likely to be noise. It needs to be explained.

I recently mentioned the BTN link to my brother, who is in Cambridge and knows the local BTN people. He produced an interesting story. When he and others were making the first monoclonals in the 1970s, by immunising mice with cell soup and seeing what random responses there were to human antigens, one of the first hits was a butyrophyllin. Although none of us had even heard of these things until DecodeME pulled one up it seems that they are a bog standard part of cell housekeeping. The hit may have reflected a particular immunogenicity for mice but most of the early hits turned out to be molecules widely expressed in good amounts.

The story is that BTNs recognise bacterial phosphoantigens. I am sceptical. I think they probably do something much more general, nothing to do with bacteria.

I wonder if anyone on continental Europe is working on BTNs?
 
Happened across a paper suggesting that stimulation of BTN2A1 on the surface of macrophages strongly affects their behavior.

I did not follow up this excellent post from @jnmaciuch a while back. So the cell with the BTNs does not jsut signal to other cells, it can get signals from other ligands via the BTNs? And microglia would be a candidate.

I thin this needs a big brainstorm.
 

A quick google threw up this 2025 meeting of a biannual gdT conference.

Maybe its worth contacting the key note speakers

Erin Adams (Chicago)

Bruno Silva Santos (IMM Lisbon)

Full programme details here:

@Jonathan Edwards
Perhaps some of these gamma delta t cell biologists might know of some BTN geneticists, given the connection?
 
The more I think about it the more I thin this is the one lead we are not tracking. James and Alex are running with CA10. OLFM4 could be a good one but it has a neuron role and we are on to neurons. Buspirone we need a clinician for but forestglip has done sterling work on the background (worth a PhD any day). BTNs we have not gnawed the bone yet?
I wonder what approach would be best to get the ball rolling for this. Maybe a similar thing to buspirone prolactin by having interested people read papers and send emails to researchers? It will probably take a while to get someone interested in that project though, despite how simple I feel the study would be.

I wonder if at the upcoming conference in Edinburgh, someone could raise this. Maybe there could be a way to talk about each of the DecodeME hits and who is doing follow up. People could also brainstorm who they think could work on each one. A room full of people capable of doing networking would be helpful.

No idea if either of those are possible, but just thinking out loud.
 
I did not follow up this excellent post from @jnmaciuch a while back. So the cell with the BTNs does not jsut signal to other cells, it can get signals from other ligands via the BTNs? And microglia would be a candidate.

I thin this needs a big brainstorm.
Not just microglia. The intracellular signaling pathway identified in the study is active in a lot of different cell types. It’s just been most studied in immune cells so far.

Blessing and a curse, since it broadens possibilities but also removes the focus for where we should be assessing BTN function.
 
I was pretty interested in what biotech's were pursuing in regards to BTN many of them got rolled into other companies and their drugs were halted.

I think a lot of it came down to this:
"Activation of γδ T-cells can be elicited by butyrophilin/butyrophilin-like molecules that are structurally similar to the immunosuppressive B7 family members. Yet how they regulate and coordinate αβ and γδ T-cell responses remains unknown. Here, we report that the BTN3A1 butyrophilin inhibits tumor-reactive αβ TCR activation by preventing segregation of N-glycosylated CD45 from the immune synapse."


Essentially this switch is messier than expexted!
 
Blessing and a curse, since it broadens possibilities but also removes the focus for where we should be assessing BTN function.

Yes, but I think I would argue that when it comes to where the two main candidates would be around neurons again, so the same strategy as what James is looking at, or a shift in an innate immune cell population that could function anywhere so it doesn't matter too much.
 
Back
Top Bottom